SCHEMBL493216

SCHEMBL493216

CN1CCN(C(c2ccccc2)C2CCC(NC(=O)COCCN(C)S(=O)(=O)c3ccc(Cl)cc3Cl)CC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 4/20 0.43
CACNA1B Q00975 4/20 0.43
CACNB1 Q02641 4/20 0.43
CACNA1C Q13936 4/20 0.43
CNR1 P21554 2/20 0.36
CNR2 P34972 2/20 0.36
MCHR1 Q99705 1/20 0.36
BDKRB1 P46663 4/20 0.35
SIGMAR1 Q99720 1/20 0.35
MAPT P10636 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
CCR5 P51681 2/20 0.34
TRPV4 Q9HBA0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL493689 0.94 CACNA2D1 (0.37) CACNA2D1CACNA1BCACNB1CACNA1CCNR1
SCHEMBL492771 0.92 MEN1 (0.38) CACNA2D1CACNA1BCACNB1CACNA1CCNR1
SCHEMBL493117 0.91 CACNA2D1 (0.42) CACNA2D1CACNA1BCACNB1CACNA1CBDKRB1
SCHEMBL493714 0.88 CACNA2D1 (0.42) CACNA2D1CACNA1BCACNB1CACNA1CBDKRB1
SCHEMBL492458 0.86 MAPT (0.38) MCHR1BDKRB1SIGMAR1MAPTTRPV4
SCHEMBL492634 0.85 CACNA2D1 (0.38) CACNA2D1CACNA1BCACNB1CACNA1CMCHR1
SCHEMBL492975 0.85 CACNA2D1 (0.37) CACNA2D1CACNA1BCACNB1CACNA1CCNR1
SCHEMBL492596 0.84 ALDH1A1 (0.37) CACNA2D1CACNA1BCACNB1CACNA1CCNR1
SCHEMBL492927 0.84 CACNA2D1 (0.36) CACNA2D1CACNA1BCACNB1CACNA1CCNR1
SCHEMBL493013 0.83 MEN1 (0.37) CACNA2D1CACNA1BCACNB1CACNA1CCNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106055-B2 Substituted amide compounds GRUENENTHAL GMBH (DE) 2012-01-31 US claimed
EP-2139851-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-01-06 EP claimed
US-20080306084-A1 Substituted Amide Compounds GRUENENTHAL GMBH (DE) 2008-12-11 US claimed
WO-2008131946-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO claimed
US-8106055-B2 Substituted amide compounds GRUENENTHAL GMBH (DE) 2012-01-31 US disclosed
EP-2139851-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2010-01-06 EP disclosed
US-20080306084-A1 Substituted Amide Compounds GRUENENTHAL GMBH (DE) 2008-12-11 US disclosed
WO-2008131946-A2 SUBSTITUTED AMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306084-A1 Substituted Amide Compounds OPRK1, NAA50, ACMSD CACNA2D1 638/4885CACNA1B 1416/4885CACNB1 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.